<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Cell Mol Med</journal-id><journal-id journal-id-type="iso-abbrev">J. Cell. Mol. Med</journal-id><journal-id journal-id-type="doi">10.1111/(ISSN)1582-4934</journal-id><journal-id journal-id-type="publisher-id">JCMM</journal-id><journal-title-group><journal-title>Journal of Cellular and Molecular Medicine</journal-title></journal-title-group><issn pub-type="ppub">1582-1838</issn><issn pub-type="epub">1582-4934</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30506878</article-id><article-id pub-id-type="pmc">6349180</article-id><article-id pub-id-type="doi">10.1111/jcmm.14041</article-id><article-id pub-id-type="publisher-id">JCMM14041</article-id><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Induction of Kr&#x000fc;ppel&#x02010;like factor 2 reduces K/BxN serum&#x02010;induced arthritis</article-title><alt-title alt-title-type="left-running-head">DAS et&#x000a0;al.</alt-title></title-group><contrib-group><contrib id="jcmm14041-cr-0001" contrib-type="author"><name><surname>Das</surname><given-names>Manjusri</given-names></name><xref ref-type="aff" rid="jcmm14041-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jcmm14041-cr-0002" contrib-type="author"><name><surname>Laha</surname><given-names>Dipranjan</given-names></name><xref ref-type="aff" rid="jcmm14041-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jcmm14041-cr-0003" contrib-type="author"><name><surname>Kanji</surname><given-names>Suman</given-names></name><xref ref-type="aff" rid="jcmm14041-aff-0002">
<sup>2</sup>
</xref></contrib><contrib id="jcmm14041-cr-0004" contrib-type="author"><name><surname>Joseph</surname><given-names>Matthew</given-names></name><xref ref-type="aff" rid="jcmm14041-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jcmm14041-cr-0005" contrib-type="author"><name><surname>Aggarwal</surname><given-names>Reeva</given-names></name><xref ref-type="aff" rid="jcmm14041-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jcmm14041-cr-0006" contrib-type="author"><name><surname>Iwenofu</surname><given-names>Obiajulu H.</given-names></name><xref ref-type="aff" rid="jcmm14041-aff-0003">
<sup>3</sup>
</xref></contrib><contrib id="jcmm14041-cr-0007" contrib-type="author"><name><surname>Pompili</surname><given-names>Vincent J.</given-names></name><xref ref-type="aff" rid="jcmm14041-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jcmm14041-cr-0008" contrib-type="author"><name><surname>Jain</surname><given-names>Mukesh K.</given-names></name><xref ref-type="aff" rid="jcmm14041-aff-0004">
<sup>4</sup>
</xref></contrib><contrib id="jcmm14041-cr-0009" contrib-type="author" corresp="yes"><name><surname>Das</surname><given-names>Hiranmoy</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-3343-0096</contrib-id><address><email>hiranmoy.das@ttuhsc.edu</email></address><xref ref-type="aff" rid="jcmm14041-aff-0002">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="jcmm14041-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Department of Internal Medicine</named-content>
<institution>The Ohio State University Medical Center</institution>
<named-content content-type="city">Columbus</named-content>
<named-content content-type="country-part">Ohio</named-content>
</aff><aff id="jcmm14041-aff-0002">
<label><sup>2</sup></label>
<named-content content-type="organisation-division">Department of Pharmaceutical Sciences</named-content>
<named-content content-type="organisation-division">School of Pharmacy</named-content>
<institution>Texas Tech University Health Sciences Center</institution>
<named-content content-type="city">Amarillo</named-content>
<named-content content-type="country-part">Texas</named-content>
</aff><aff id="jcmm14041-aff-0003">
<label><sup>3</sup></label>
<named-content content-type="organisation-division">Department of Pathology</named-content>
<named-content content-type="organisation-division">College of Medicine</named-content>
<institution>The Ohio State University</institution>
<named-content content-type="city">Columbus</named-content>
<named-content content-type="country-part">Ohio</named-content>
</aff><aff id="jcmm14041-aff-0004">
<label><sup>4</sup></label>
<named-content content-type="organisation-division">Department of Internal Medicine</named-content>
<institution>Case Western Reserve University</institution>
<named-content content-type="city">Cleveland</named-content>
<named-content content-type="country-part">Ohio</named-content>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Hiranmoy Das, Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX.<break/>
Email: <email>hiranmoy.das@ttuhsc.edu</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>03</day><month>12</month><year>2018</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2019</year></pub-date><volume>23</volume><issue>2</issue><issue-id pub-id-type="doi">10.1111/jcmm.2019.23.issue-2</issue-id><fpage>1386</fpage><lpage>1395</lpage><history><date date-type="received"><day>06</day><month>4</month><year>2018</year></date><date date-type="rev-recd"><day>18</day><month>9</month><year>2018</year></date><date date-type="accepted"><day>29</day><month>10</month><year>2018</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> Copyright &#x000a9; 2019 Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2018 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley &#x00026; Sons Ltd and Foundation for Cellular and Molecular Medicine.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JCMM-23-1386.pdf"/><abstract id="jcmm14041-abs-0001"><title>Abstract</title><p>Kr&#x000fc;ppel&#x02010;like factor 2 (<styled-content style="fixed-case">KLF</styled-content>2) critically regulates activation and function of monocyte, which plays important pathogenic role in progressive joint destruction in rheumatoid arthritis (<styled-content style="fixed-case">RA</styled-content>). It is yet to be established the molecular basis of <styled-content style="fixed-case">KLF</styled-content>2&#x02010;mediated regulation of monocytes in <styled-content style="fixed-case">RA</styled-content> pathogenesis. Herein, we show that a class of compound, <styled-content style="fixed-case">HDAC</styled-content> inhibitors (<styled-content style="fixed-case">HDAC</styled-content>i) induced <styled-content style="fixed-case">KLF</styled-content>2 expression in monocytes both <italic>in vitro</italic> and <italic>in vivo</italic>. <styled-content style="fixed-case">KLF</styled-content>2 level was also elevated in tissues, such as bone marrow, spleen and thymus in mice after infusion of <styled-content style="fixed-case">HDAC</styled-content>i. Importantly, <styled-content style="fixed-case">HDAC</styled-content>i significantly reduced osteoclastic differentiation of monocytes with the up&#x02010;regulation of <styled-content style="fixed-case">KLF</styled-content>2 and concomitant down&#x02010;regulation of matrixmetalloproteinases both in the expression level as well as in the protein level. In addition, <styled-content style="fixed-case">HDAC</styled-content>i reduced K/BxN serum&#x02010;induced arthritic inflammation and joint destruction in mice in a dose&#x02010;dependent manner. Finally, co&#x02010;immunoprecipitation and overexpression studies confirmed that <styled-content style="fixed-case">KLF</styled-content>2 directly interacts with <styled-content style="fixed-case">HDAC</styled-content>4 molecule in cells. These findings provide mechanistic evidence of <styled-content style="fixed-case">KLF</styled-content>2&#x02010;mediated regulation of K/BxN serum&#x02010;induced arthritic inflammation.</p></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jcmm14041-kwd-0001"><styled-content style="fixed-case">HDAC</styled-content> inhibitors</kwd><kwd id="jcmm14041-kwd-0002">inflammation</kwd><kwd id="jcmm14041-kwd-0003"><styled-content style="fixed-case">KLF</styled-content>2</kwd><kwd id="jcmm14041-kwd-0004">monocytes</kwd><kwd id="jcmm14041-kwd-0005">osteoclasts</kwd><kwd id="jcmm14041-kwd-0006">rheumatoid arthritis</kwd></kwd-group><funding-group><award-group><funding-source>National Institute of Arthritis and Musculoskeletal and Skin Diseases</funding-source><award-id>R01AR068279</award-id></award-group><award-group><funding-source>National Eye Institute</funding-source><award-id>1R41EY024217</award-id></award-group><award-group><funding-source>National Institute on Aging</funding-source></award-group><award-group><funding-source>NIH</funding-source><award-id>STTR 1R41AG057242 (NIA)</award-id></award-group></funding-group><counts><fig-count count="6"/><table-count count="0"/><page-count count="10"/><word-count count="6101"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jcmm14041</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>February 2019</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:5.5.6 mode:remove_FC converted:28.01.2019</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jcmm14041-cit-1001">
<string-name>
<surname>Das</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Laha</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Kanji</surname>
<given-names>S</given-names>
</string-name>, et&#x000a0;al. <article-title>Induction of Kr&#x000fc;ppel&#x02010;like factor 2 reduces K/BxN serum&#x02010;induced arthritis</article-title>. <source xml:lang="en">J Cell Mol Med</source>. <year>2019</year>;<volume>23</volume>:<fpage>1386</fpage>&#x02013;<lpage>1395</lpage>. <pub-id pub-id-type="doi">10.1111/jcmm.14041</pub-id>
</mixed-citation>
</p></notes></front><body><sec id="jcmm14041-sec-0001"><label>1</label><title>INTRODUCTION</title><p>Rheumatoid arthritis (RA) is a chronic autoimmune disorder manifested by progressive destructions of synovial joints, articular cartilages and bones.<xref rid="jcmm14041-bib-0001" ref-type="ref">1</xref> It is the most common form of inflammatory arthritis resulting in disability.<xref rid="jcmm14041-bib-0002" ref-type="ref">2</xref> Even though many current drugs have the potential to reduce pain at the early stage of this disease, the long&#x02010;term effect are highly associated with undesired side effects.<xref rid="jcmm14041-bib-0003" ref-type="ref">3</xref> Immune cells are critical in initiating pathogenesis of RA.<xref rid="jcmm14041-bib-0004" ref-type="ref">4</xref> The recruitment of monocytes to the inflammatory sites triggers the secretion of proinflammatory effectors leads to tissue destruction.<xref rid="jcmm14041-bib-0005" ref-type="ref">5</xref> Recruited monocytes differentiate into synovial tissue macrophages and produce a number of inflammatory mediators that activate surrounding resident cells.<xref rid="jcmm14041-bib-0006" ref-type="ref">6</xref> They also differentiate into osteoclasts, which are mainly responsible for subchondrial bone destruction in RA.<xref rid="jcmm14041-bib-0007" ref-type="ref">7</xref> These osteoclasts can be formed not only from the mature tissue macrophages but also from the immature cells of the monocytes&#x02010;macrophage lineage. Therefore, monocytes are central to the pathophysiology of RA, and they have been found to be activated in RA patients too.<xref rid="jcmm14041-bib-0008" ref-type="ref">8</xref> Hence, identifying a better regulatory mechanism for monocyte activation in RA will help in creating better management of this disease using more specific targets.</p><p>Kr&#x000fc;ppel&#x02010;like transcription factor (KLF)s are involved in regulation of terminal differentiation of several immune cells. Lung KLF (LKLF) or KLF2 plays a significant regulatory role in haematopoietic cell biology including cell quiescence, cell proliferation, differentiation and survival.<xref rid="jcmm14041-bib-0009" ref-type="ref">9</xref>, <xref rid="jcmm14041-bib-0010" ref-type="ref">10</xref> KLF2 also regulates myeloid cell activation and function.<xref rid="jcmm14041-bib-0011" ref-type="ref">11</xref> During inflammation, KLF2 acts as a potent inhibitor of transcription factors like NF&#x02010;&#x003ba;B and AP1, as well as of hypoxia&#x02010;related HIF&#x02010;1&#x003b1; protein.<xref rid="jcmm14041-bib-0012" ref-type="ref">12</xref> Importantly, KLF2 is essential for embryonic erythropoiesis and KLF2&#x02010;deficient mice are embryonic lethal because of the leaky blood vessels and haemorrhages.<xref rid="jcmm14041-bib-0013" ref-type="ref">13</xref>
</p><p>Kr&#x000fc;ppel&#x02010;like factor 2 is a negative regulator of monocyte activation and osteoclast differentiation, directs them towards quiescent state.<xref rid="jcmm14041-bib-0011" ref-type="ref">11</xref>, <xref rid="jcmm14041-bib-0014" ref-type="ref">14</xref> The current study focuses on assessing role of a special class of pharmacological compounds, histone deacetylase inhibitors (HDACi) in modulation of KLF2 in monocytes both in&#x000a0;vitro and in&#x000a0;vivo. HDACi have been used clinically for the treatment of various cancer malignancies.<xref rid="jcmm14041-bib-0015" ref-type="ref">15</xref> HDACs are well known for their role in chromatin remodelling,<xref rid="jcmm14041-bib-0016" ref-type="ref">16</xref> and also regulate large number of non&#x02010;histone proteins, which controls cell processes associated to various disease conditions.<xref rid="jcmm14041-bib-0017" ref-type="ref">17</xref> Evidence show that HDACi controls NF&#x003ba;B&#x02010;driven inflammatory responses through cell cycle arrest.<xref rid="jcmm14041-bib-0018" ref-type="ref">18</xref> However, the effect of HDACi on inflammatory response varies according to the cell type and stimulus. As cell cycle arrest leads to cell quiescence, and KLF2 is induced upon cell quiescence, we were interested to know whether HDACi can mediate induction of KLF2. Among the common HDACi are suberoylanilide hydroxamic acid (SAHA), entinostat (SNDx&#x02010;275 or MS&#x02010;275) and Trichostatin A (TSA) are of consideration. In addition, it is yet to be defined how HDACi regulate myeloid KLF2 and RA pathogenesis. To investigate the efficacy of HDACi against RA progression and to delineate the mechanistic evidence have driven us to explore this intrigued pathogenesis.</p></sec><sec id="jcmm14041-sec-0002"><label>2</label><title>MATERIALS AND METHODS</title><sec id="jcmm14041-sec-0003"><label>2.1</label><title>Isolation and culture of monocytes from murine bone marrow</title><p>Bone marrow (BM) cells were isolated from the femurs of 6&#x02010; to 8&#x02010;week&#x02010;old C57BL/6 mice, and cultured in DMEM medium (Sigma) supplemented with 10% foetal bovine serum (ThermoFisher, Grand Island, NY, USA) at 37&#x000b0;C in a 5% CO<sub>2</sub> atmosphere for plastic adherence. Adhered monocytes were either stimulated with suberoylanilide hydroxamic acid (SAHA from Sigma), entinostat (SNDx&#x02010;275 or MS&#x02010;275; Cayman Chemical Company, Ann Arbor, MI, USA) and Trichostatin A (TSA from Sigma) for either 24 or 48&#x000a0;hours or cultured without stimulus (DMSO, vehicle) for control.</p></sec><sec id="jcmm14041-sec-0004"><label>2.2</label><title>
<italic>In vivo</italic> stimulation of mice with HDACi</title><p>To investigate whether systemic stimulation with HDACi to the mice have any effect on immune cell&#x02010;rich tissues, three mice per group were injected intra peritoneal (i.p.) with MS275 (5&#x000a0;mg/kg BW in 50&#x000a0;&#x003bc;L DMSO) and TSA (10&#x000a0;mg/kg BW in 50&#x000a0;&#x003bc;L DMSO) or DMSO (50&#x000a0;&#x003bc;L, as a control). After 24&#x000a0;hours of HDACi injections, BM, spleen and thymus were harvested. A part of the tissues was homogenized and RNA was extracted, and another part was subjected to protein extraction.</p></sec><sec id="jcmm14041-sec-0005"><label>2.3</label><title>Isolation of human monocytes</title><p>Fresh human peripheral blood (n&#x000a0;=&#x000a0;6) was collected with an approved IRB and written consent from donors from The Ohio State University Medical Center, Columbus, OH and processed following earlier described protocol.<xref rid="jcmm14041-bib-0011" ref-type="ref">11</xref>, <xref rid="jcmm14041-bib-0019" ref-type="ref">19</xref> In, brief, peripheral blood mononuclear cells were isolated from freshly collected blood using Ficoll&#x02010;Paque density centrifugation. CD14<sup>+</sup> cells were isolated by using an AutoMACS device, CD14<sup>+</sup> antibody and reagents (all from Miltenyi Biotec, San Diego, CA, USA) following earlier established protocol.<xref rid="jcmm14041-bib-0011" ref-type="ref">11</xref>, <xref rid="jcmm14041-bib-0020" ref-type="ref">20</xref> A part of the CD14<sup>+</sup> cells was used for RNA extraction, and another part was subjected to protein extraction.</p></sec><sec id="jcmm14041-sec-0006"><label>2.4</label><title>Real time RT&#x02010;PCR analysis</title><p>Total RNA was isolated from BM&#x02010;derived monocytes, RAW 264.7 cell (ATCC, Manassas, VA, USA) and human peripheral blood&#x02010;derived monocytes after 24&#x000a0;hours of HDACi stimulation, or murine tissues after infusion with HDACi to mice using a RNeasy Kit (Qiagen, ThermoFisher). One microgram of RNA was used for synthesis of cDNA using oligo dT (Invitrogen, ThermoFisher) primer. Real&#x02010;time RT&#x02010;PCR was performed with 1&#x000a0;&#x003bc;L of cDNA for the gene&#x02010;specific primers of KLF2, matrixmetalloproteinase 3 (MMP3), MMP9 and MMP13, keeping GAPDH as an internal control using a standard SYBR green Taqman protocol, and a real&#x02010;time PCR machine (MX3000P; Stratagene, Santa Clara, CA, USA). Relative fold&#x02010;expression levels of stated genes were measured considering respective unstimulated cells or tissues (added DMSO) as controls. Experiments were performed in triplicate and were repeated at least three times.</p></sec><sec id="jcmm14041-sec-0007"><label>2.5</label><title>Osteoclast differentiation</title><p>Bone marrow cells were collected from femurs of mice were induced for osteoclastic differentiation in&#x000a0;vitro in the presence or absence of HDACi (SAHA or MS&#x02010;275 both 10&#x000a0;nmol/L). In, brief, BM cells were cultured overnight at 37&#x000b0;C incubator with 5% CO<sub>2</sub> in &#x003b1;MEM containing 10% heat inactivated foetal bovine serum in the presence of 20&#x000a0;ng/mL M&#x02010;CSF (R &#x00026; D Systems, Minneapolis, MN, USA). Next day, non&#x02010;adherent cells were collected and incubated for an additional 6&#x000a0;days in &#x003b1;MEM medium with 20&#x000a0;ng/mL M&#x02010;CSF, and 50&#x000a0;ng/mL GST&#x02010;RANKL.<xref rid="jcmm14041-bib-0021" ref-type="ref">21</xref> Fresh medium was replaced every alternate day and HDACi was added to the medium as needed. At days 3 and 6 of differentiation, the cells were stained for TRAP staining using an acid phosphatase, leukocyte; Trap Staining Kit (Sigma) and was viewed and imaged with a fluorescence microscope (Nikon, Axioplan2; Carl Zeiss). TRAP&#x02010;positive multinucleated cells (3 nuclei, DAPI positive) were counted as osteoclast&#x02010;like cells.</p></sec><sec id="jcmm14041-sec-0008"><label>2.6</label><title>Induction of arthritis</title><p>K/BxN mice were generated by crossing KRN, TCR&#x02010;transgenic B6 mice (kind gift from Dr. Diane Mathis, Harvard Medical School, Boston, MA, USA) with NOD mice (Jackson Laboratory, Bar Harbor, ME, USA) following established protocol.<xref rid="jcmm14041-bib-0022" ref-type="ref">22</xref> K/BxN serum was collected from 6&#x02010; to 8&#x02010;week&#x02010;old arthritic K/BxN mice and pooled for each experiment. Four groups (n&#x000a0;=&#x000a0;8 for each group) of mice (C57BL/6 background 6&#x02010;8&#x000a0;weeks old, both male and female) were induced by i.p. injection of 150&#x000a0;&#x003bc;L of K/BxN serum on days 0 and 2 following earlier established protocol.<xref rid="jcmm14041-bib-0023" ref-type="ref">23</xref> Three groups were treated with HDAC inhibitors during the course of arthritis development for 7&#x000a0;days (control = no treatment; treatment with SAHA, 10&#x000a0;mg/kg body weight; treatment with SAHA, 30&#x000a0;mg/kg body weight; and treatment with MS275, 5&#x000a0;mg/kg body weight). Mice were observed everyday and measured for ankle thickness using a microcaliper (Mitutoyo, MSC Industrial Supply Co. USA), and finally, sacrificed on day 8 following first injection of K/BxN serum administrations. Hindlimbs were harvested and were subjected to histopathological analysis.</p></sec><sec id="jcmm14041-sec-0009"><label>2.7</label><title>Histological assessment of arthritis</title><p>Arthritis was assessed by histological examination as described,<xref rid="jcmm14041-bib-0014" ref-type="ref">14</xref> with some modifications. Limbs were fixed in periodate&#x02010;lysine&#x02010;paraformaldehyde for overnight and decalcified in 10% EDTA (BDH Chemicals, Victoria, Australia) and 7.5% polyvinylpyrolidone (Sigma) in Tris buffer (pH 6.95) for 7&#x02010;10&#x000a0;days and processed for paraffin embedding. Tissues were sectioned with 5&#x000a0;&#x003bc;mol/L thickness, placed on aminoalkylsilane&#x02010;coated slides, and stained for routine histology with haematoxylin and eosin (H&#x00026;E). Five defined pathological features were graded for severity from 0 (normal) to 5 (severe), according to established protocol,<xref rid="jcmm14041-bib-0024" ref-type="ref">24</xref> and in a blinded manner. Soft tissue inflammation, assessed in the infrapatellar fat pads, joint capsule, and the area adjacent to the periosteal sheath, was graded according to the extent of cellular infiltration and angiogenesis. Joint space exudate was identified as leucocytes scattered discretely or in aggregates in the joint space. Synovitis (synovial hyperplasia) was defined as hyperplasia of the synovium, but did not include pannus formation. Pannus was defined as hypertrophic synovial tissue forming a tight junction with the articular surface. Evaluation of cartilage and bone damage was based on loss of cartilage matrix, disruption and loss of cartilage surface, and the extent and depth of the subchondral bone erosion.<xref rid="jcmm14041-bib-0025" ref-type="ref">25</xref> A trained pathologist, Department of Pathology, The Ohio State University Medical Center performed the histomorphometric analyses from multiple H&#x00026;E sections.</p></sec><sec id="jcmm14041-sec-0010"><label>2.8</label><title>Western blotting</title><p>Total protein analysis was performed with the standard Western blot (WB) method with equal amount of proteins isolated from human primary monocytes or RAW 264.7 cells that were stimulated for 24&#x000a0;hours with HDACi or from homogenized murine tissues after infusion with&#x000a0;HDACi to the mice for 24&#x000a0;hours were fractionated in a SDS&#x02010;polyacrylamide gel. WB analysis was performed with KLF2 (Abcam Cambridge, MA, USA and Santa Cruz Biotech, Dallas, TX, USA), MMP9, AcHistone3, HDAC1, HDAC3, HDAC4, p65, &#x003b2;&#x02010;actin and GAPDH (all from Cell Signaling Technology, Danvers, MA, USA) antibodies.</p></sec><sec id="jcmm14041-sec-0011"><label>2.9</label><title>Co&#x02010;immunoprecipitation assays</title><p>COS&#x02010;7 (ATCC) cells were transfected with the indicated expression plasmids (KLF2&#x02010;Myc and HADC1&#x02010;4 all Flag tagged) using Lipofectamine 2000 (ThermoFisher Scientific) transfection reagent following the manufacturer's protocol, and harvested in RIPA buffer after 48&#x000a0;hours of transfection. One milligram of each lysates was subjected to immunoprecipitation with 5&#x000a0;&#x003bc;g of &#x003b1;Myc monoclonal antibody (ThermoFisher) at 4&#x000b0;C for 2&#x000a0;hours followed by incubation with protein A/G Sepharose beads (Abcam Inc) for overnight at 4&#x000b0;C. The beads were washed and proteins were separated by SDS&#x02010;PAGE as previously described<xref rid="jcmm14041-bib-0011" ref-type="ref">11</xref> and developed with anti&#x02010;Flag antibody (Sigma).</p></sec><sec id="jcmm14041-sec-0012"><label>2.10</label><title>KLF2 overexpression in RAW264.7 cells by adenoviral infection</title><p>RAW 264.7 cells were infected with control (Ad&#x02010;GFP) or KLF2 (Ad&#x02010;KLF2) virus at 50 MOI. In general, ~40%&#x02010;50% infection was achieved within 24&#x02010;48&#x000a0;hours of incubation with adenovirus at which time cells were harvested and lysed for protein analysis.</p></sec><sec id="jcmm14041-sec-0013"><label>2.11</label><title>Statistical analysis</title><p>Values were expressed as mean&#x000a0;&#x000b1;&#x000a0;SEM and statistical analysis was performed by ANOVA. Student's <italic>t</italic> test was performed and the results were considered significant when <italic>P</italic>&#x02010;values were &#x0003c;0.05.</p></sec></sec><sec id="jcmm14041-sec-0014"><label>3</label><title>RESULTS</title><sec id="jcmm14041-sec-0015"><label>3.1</label><title>Effect of HDAC inhibitors on KLF2 expression in monocytes</title><p>To test the effect of HDACi on KLF2 gene expression, three different types of HDACi (MS275, SAHA and TSA) at various concentrations (1&#x02010;50&#x000a0;nmol/L) were added to the murine monocytic cells (RAW 264.7), and DMSO was added as a vehicle control. After 24&#x000a0;hours of incubation, RNA was isolated from harvested cells, were subjected to KLF2 gene expression using the quantitative RT&#x02010;PCR method, and simultaneously cell viability was verified by a Trypan blue exclusion test. All HDACi induced KLF2 at various degrees (2&#x02010; to 17&#x02010;fold, Figure&#x000a0;<xref rid="jcmm14041-sup-0001" ref-type="supplementary-material">S1</xref>); however, 50&#x000a0;nmol/L concentrations reduced cell viability significantly (data not shown). For subsequent studies sublethal dose, 10&#x000a0;nmol/L of HDACi were used for testing in mouse primary BM monocytes. Similar to the cell line, all HDAC inhibitors also induced KLF2 in primary BM monocytes at various degrees from 20&#x02010; to 40&#x02010;fold (Figure&#x000a0;<xref rid="jcmm14041-fig-0001" ref-type="fig">1</xref>A). We next tested one of the HDACi (MS275) in mouse BM monocytes or RAW 264.7 or human peripheral blood&#x02010;derived (PB&#x02010;) monocytes. Cells were incubated with 10&#x000a0;nmol/L HDACi (MS275) and DMSO was considered as basal control similar to the earlier experiments. Isolated RNA was subjected to real&#x02010;time RT&#x02010;PCR for KLF2 expression, and the relative fold expression was graphically presented considering GAPDH as an internal control (Figure&#x000a0;<xref rid="jcmm14041-fig-0001" ref-type="fig">1</xref>B). A 20&#x02010;fold higher expression of KLF2 in mouse BM monocytes were found with MS275 compared to the untreated (control) cells. Whereas the KLF2 expression level was almost sixfold higher in RAW 264.7 cell after incubation with MS275 compared to the control cells. Interestingly, in human PB&#x02010;monocyte, it showed a 43&#x02010;fold elevation in KLF2 expression after treatment with MS275 compared to untreated cells. To confirm, KLF2 expression was translated into protein, WB analysis was performed. WB data revealed that the protein levels of KLF2 were markedly higher in both human primary PB&#x02010;monocytes (Figure&#x000a0;<xref rid="jcmm14041-fig-0001" ref-type="fig">1</xref>C) and murine transformed monocytic cells after stimulation with various HDACi at multiple time&#x02010;points compared to unstimulated control cells (Figure&#x000a0;<xref rid="jcmm14041-fig-0001" ref-type="fig">1</xref>C). The expression level of KLF2 was not consistent with all HDACi in the context of time&#x02010;points. For example, highest expression was noticed with TSA at 12&#x000a0;hours, whereas with SAHA and MS275, it was at 48&#x000a0;hours time&#x02010;point. The Western blot data were quantified and shown graphically (Figure&#x000a0;<xref rid="jcmm14041-fig-0001" ref-type="fig">1</xref>E,F). Nevertheless, these data indicated that HDACi induced KLF2 expression in monocytes both in the transcriptional level as well in the protein level.</p><fig fig-type="Figure" xml:lang="en" id="jcmm14041-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>
<styled-content style="fixed-case">HDAC</styled-content> inhibitor induces <styled-content style="fixed-case">KLF</styled-content>2 expression in monocytes. (A) Real&#x02010;time <styled-content style="fixed-case">RT</styled-content>&#x02010;<styled-content style="fixed-case">PCR</styled-content> was performed to evaluate the level of relative <styled-content style="fixed-case">KLF</styled-content>2 expression in <styled-content style="fixed-case">RNA</styled-content> isolated from mouse primary bone marrow&#x02010;derived monocytes (n&#x000a0;=&#x000a0;3), after treating with 10&#x000a0;nmol/L of various <styled-content style="fixed-case">HDAC</styled-content>i (<styled-content style="fixed-case">MS</styled-content>275, <styled-content style="fixed-case">SAHA</styled-content> or <styled-content style="fixed-case">TSA</styled-content>) for 24&#x000a0;h, and without stimulus (<styled-content style="fixed-case">DMSO</styled-content>) was considered as a base line control of <styled-content style="fixed-case">KLF</styled-content>2 expression, and the relative fold expression was graphically presented. <styled-content style="fixed-case">GAPDH</styled-content> was considered as an internal control. Experiments were performed in triplicate. (B) Similar experiment was performed with mouse primary bone marrow&#x02010;derived monocytes (n&#x000a0;=&#x000a0;3), mouse monocyte cell line (<styled-content style="fixed-case">RAW</styled-content> 264.7) and human primary peripheral blood&#x02010;derived monocytes (n&#x000a0;=&#x000a0;3) after treating with 10&#x000a0;nmol/L <styled-content style="fixed-case">HDAC</styled-content>i (<styled-content style="fixed-case">MS</styled-content>275) for 24&#x000a0;h, and data are presented graphically. (C, D) Similar experiments were performed with mouse bone marrow monocytes, <styled-content style="fixed-case">RAW</styled-content> 264.7, and human primary peripheral blood&#x02010;derived monocytes after stimulation with 10&#x000a0;nmol/L of <styled-content style="fixed-case">TSA</styled-content>, or <styled-content style="fixed-case">MS</styled-content>275 or <styled-content style="fixed-case">SAHA</styled-content>, and proteins were evaluated at various time&#x02010;points as stated, and evaluated for <styled-content style="fixed-case">KLF</styled-content>2 expression using Western blot methods using &#x003b2;&#x02010;actin as an internal control. (E, F) Quantified Western blot data of figures C, D are presented graphically</p></caption><graphic id="nlm-graphic-1" xlink:href="JCMM-23-1386-g001"/></fig></sec><sec id="jcmm14041-sec-0016"><label>3.2</label><title>Tissue expressions of KLF2 in mice after injection with HDAC inhibitor</title><p>To investigate whether HDACi injection to the mice has any effect on KLF2 level in immune rich tissues, mice were injected (i.p.) with MS275 (5&#x000a0;mg/kg BW in 200&#x000a0;&#x003bc;L DMSO) and Trichostatin A (TSA, 10&#x000a0;mg/kg BW in 200&#x000a0;&#x003bc;L DMSO) or DMSO (as a control). After 24&#x000a0;hours of HDACi injections, BM, spleen and thymus tissues were harvested and analysed. Real&#x02010;time RT&#x02010;PCR analysis revealed that significant higher level of KLF2 expression in all tissues after injection with both HDAC inhibitors (MS275 or TSA) compared to vehicle injected controls, except MS275 in thymus, where little elevation of KLF2 was noticed (Figure&#x000a0;<xref rid="jcmm14041-fig-0002" ref-type="fig">2</xref>A). Western blot analysis (Figure&#x000a0;<xref rid="jcmm14041-fig-0002" ref-type="fig">2</xref>B) for KLF2 revealed that the level of KLF2 was markedly higher in all tissues where animals were injected with either of the HDAC inhibitors (MS275 or TSA) compared to the control animals. We also investigated whether HDAC inhibitors activate histones for transcriptional activities. Indeed, we found that level of acetylated Histone 3 (Ac&#x02010;H3) was markedly elevated in all tissues of animals that were injected with either of the HDAC inhibitors (MS275 or TSA) compared to the control animals. The Western blot data were quantified and shown graphically (Figure&#x000a0;<xref rid="jcmm14041-fig-0002" ref-type="fig">2</xref>C). These data indicates that KLF2 level both in gene expression and protein was up&#x02010;regulated in&#x000a0;vivo in BM, spleen and thymus tissues after injection with HDACi either MS275 or TSA.</p><fig fig-type="Figure" xml:lang="en" id="jcmm14041-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>
<styled-content style="fixed-case">HDAC</styled-content> inhibitor induces <styled-content style="fixed-case">KLF</styled-content>2 expression in various tissues in mice. (A) Three mice per group were injected (ip) with <styled-content style="fixed-case">HDAC</styled-content>i, and after 24&#x000a0;h bone marrow, spleen and thymus were harvested. Tissues were homogenized and part was subjected to real&#x02010;time <styled-content style="fixed-case">RT</styled-content>&#x02010;<styled-content style="fixed-case">PCR</styled-content> to evaluate the level of relative <styled-content style="fixed-case">KLF</styled-content>2 expression in <styled-content style="fixed-case">RNA</styled-content>. Vehicle control injected mice was considered as a base line control for <styled-content style="fixed-case">KLF</styled-content>2 expression and the relative fold expression was graphically presented for various tissues. <styled-content style="fixed-case">GAPDH</styled-content> was considered as an internal control. <styled-content style="fixed-case">PCR</styled-content> experiments were performed in triplicate. (B) Other part of the tissues was subjected to protein extraction, and followed by Western blot analysis for <styled-content style="fixed-case">KLF</styled-content>2 expression. The levels of <styled-content style="fixed-case">KLF</styled-content>2 expression and acetylated Histone 3 were shown along with <styled-content style="fixed-case">GAPDH</styled-content> (as an internal control). (C) Quantified Western blot data of stated molecules are presented graphically</p></caption><graphic id="nlm-graphic-3" xlink:href="JCMM-23-1386-g002"/></fig></sec><sec id="jcmm14041-sec-0017"><label>3.3</label><title>Effect of HDAC inhibitor on osteoclastic differentiation of monocytes</title><p>We next sought to find whether HDAC inhibitors have any effect on monocyte differentiation to osteoclasts, as they are the important cells in arthritic tissue damages.<xref rid="jcmm14041-bib-0026" ref-type="ref">26</xref>, <xref rid="jcmm14041-bib-0027" ref-type="ref">27</xref> A murine monocytic cell line (RAW 264.7) and murine primary BM cells were stimulated in&#x000a0;vitro using IL&#x02010;4 and sRANKL<xref rid="jcmm14041-bib-0014" ref-type="ref">14</xref> in the presence or absence of non&#x02010;toxic doses of HDAC inhibitors; SAHA (10&#x000a0;nmol/L) or MS275 (10&#x000a0;nmol/L). TRAP staining showed that the osteoclast differentiation of monocytic cells (Figure&#x000a0;<xref rid="jcmm14041-fig-0003" ref-type="fig">3</xref>A) or primary BM cells (Figure&#x000a0;<xref rid="jcmm14041-fig-0003" ref-type="fig">3</xref>B) was remarkably reduced in the presence of HDAC inhibitors. Monocytic cells and BM cells did not adhere to the culture plate and remained alive during the course of differentiation.</p><fig fig-type="Figure" xml:lang="en" id="jcmm14041-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>
<styled-content style="fixed-case">HDAC</styled-content> inhibitors reduce osteoclastic differentiation of monocytes. Murine monocytic cell line (<styled-content style="fixed-case">RAW</styled-content> 264.7) (A) and murine primary bone marrow cells (B) were subjected to osteoclastic differentiation in the presence or absence of <styled-content style="fixed-case">HDAC</styled-content>i, such as <styled-content style="fixed-case">SAHA</styled-content> (10&#x000a0;nmol/L) and <styled-content style="fixed-case">MS</styled-content>275 (10&#x000a0;nmol/L). <styled-content style="fixed-case">TRAP</styled-content> staining was performed during the course of osteoclastic differentiation at days 3 and 6. Images were depicted here. Scale bar indicates 10&#x000a0;&#x003bc;mol/L</p></caption><graphic id="nlm-graphic-5" xlink:href="JCMM-23-1386-g003"/></fig></sec><sec id="jcmm14041-sec-0018"><label>3.4</label><title>Factors associated with HDAC inhibitor&#x02010;mediated osteoclastic differentiation</title><p>To further investigate the reasons for HDAC inhibitor&#x02010;mediated reduced osteoclastic differentiation of monocytes, we analysed live cells in next sets of experiments. Real&#x02010;time PCR data revealed that the expression of MMP3, 9 and 13 were significantly reduced in both RAW 264.7 (Figure&#x000a0;<xref rid="jcmm14041-fig-0004" ref-type="fig">4</xref>A) and primary BM cells (Figure&#x000a0;<xref rid="jcmm14041-fig-0004" ref-type="fig">4</xref>B) in the presence of HDAC inhibitors either MS275 or SAHA compared to without HDAC inhibitors. Instead, KLF2 level was significantly higher in both RAW 264.7 (Figure&#x000a0;<xref rid="jcmm14041-fig-0004" ref-type="fig">4</xref>C) and primary BM cells (Figure&#x000a0;<xref rid="jcmm14041-fig-0004" ref-type="fig">4</xref>D) in the presence of HDAC inhibitors compared to controls. Similar results were observed in both days (days 3 and 6); data presented here is from day 6 of differentiation. Collectively, these data showed a direct correlation of up&#x02010;regulation of KLF2 associated with down&#x02010;regulation of MMPs in the monocytes in the presence of HDAC inhibitors. To confirm whether gene expression was translated to protein, Western blot analysis was performed; NF&#x003ba;B (p65) and MMP9 levels were increased during the course of osteoclastic differentiation (Figure&#x000a0;<xref rid="jcmm14041-fig-0004" ref-type="fig">4</xref>E). However, when cells were treated with HDACi during the course of osteoclastic differentiation, MMP9 and NF&#x003ba;B (p65) levels were markedly decreased concomitantly KLF2 level was increased (Figure&#x000a0;<xref rid="jcmm14041-fig-0004" ref-type="fig">4</xref>F). The Western blot data was quantified and shown graphically (Figure&#x000a0;<xref rid="jcmm14041-sup-0002" ref-type="supplementary-material">S2</xref>).</p><fig fig-type="Figure" xml:lang="en" id="jcmm14041-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Reduced osteoclastic differentiation is associated with reduced levels of <styled-content style="fixed-case">MMP</styled-content>s and increased level of <styled-content style="fixed-case">KLF</styled-content>2. Total <styled-content style="fixed-case">RNA</styled-content> was isolated from murine monocytic cell (<styled-content style="fixed-case">RAW</styled-content> 264.7) (A, C) and murine primary bone marrow cells (B, D) that were subjected to osteoclastic differentiation in the presence or absence of <styled-content style="fixed-case">HDAC</styled-content>i, such as <styled-content style="fixed-case">SAHA</styled-content> (10&#x000a0;nmol/L), <styled-content style="fixed-case">MS</styled-content>275 (10&#x000a0;nmol/L) or <styled-content style="fixed-case">TSA</styled-content> (10&#x000a0;nmol/L), and were subjected to real&#x02010;time <styled-content style="fixed-case">RT</styled-content>&#x02010;<styled-content style="fixed-case">PCR</styled-content> analysis for expression levels of <styled-content style="fixed-case">MMP</styled-content>3, 9 and 13 along with <styled-content style="fixed-case">KLF</styled-content>2 keeping <styled-content style="fixed-case">GAPDH</styled-content> as an internal control, shown graphically. <styled-content style="fixed-case">RT</styled-content>&#x02010;<styled-content style="fixed-case">PCR</styled-content> experiments were performed in triplicate. The experiment was performed at least three times, and (*) indicates statistical significance (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05) when compared to the respective controls. (E) Western blot analysis was performed during the course of osteoclastic differentiation of <styled-content style="fixed-case">RAW</styled-content> 264.7 cells for <styled-content style="fixed-case">KLF</styled-content>2, <styled-content style="fixed-case">NF</styled-content>&#x003ba;B (p65) and <styled-content style="fixed-case">MMP</styled-content>9 proteins keeping <styled-content style="fixed-case">GAPDH</styled-content> as an internal control. (F) Western blot analysis was performed during the course of osteoclastic differentiation of <styled-content style="fixed-case">RAW</styled-content> 264.7 cells as indicated for <styled-content style="fixed-case">KLF</styled-content>2, <styled-content style="fixed-case">NF</styled-content>&#x003ba;B (p65) and <styled-content style="fixed-case">MMP</styled-content>9 proteins keeping <styled-content style="fixed-case">GAPDH</styled-content> as an internal control in the presence or absence of <styled-content style="fixed-case">HDAC</styled-content>i</p></caption><graphic id="nlm-graphic-7" xlink:href="JCMM-23-1386-g004"/></fig></sec><sec id="jcmm14041-sec-0019"><label>3.5</label><title>Effect of HDAC inhibitors in K/BxN serum&#x02010;induced arthritis in mice</title><p>As HDAC inhibitor induced KLF2 in monocytes and reduced osteoclastic differentiation of monocytes, we next tested whether HDAC inhibitor has any effect on arthritic inflammation and severity in joint destruction in mice. Mice were induced arthritis using K/BxN serum and treated with HDAC inhibitors (either SAHA, 10&#x000a0;mg/kg body weight; or SAHA 30&#x000a0;mg/kg body weight; or MS275, 5&#x000a0;mg/kg body weight) during the course of arthritis development for 7&#x000a0;days. Ankles were measured, and found that a significant reduction in inflammation after injection of HDAC inhibitor with SAHA 30&#x000a0;mg/kg body weight; or MS275, 5&#x000a0;mg/kg body weight from day 2 to day 7 (Figure&#x000a0;<xref rid="jcmm14041-fig-0005" ref-type="fig">5</xref>A). When the lower dose of SAHA (10&#x000a0;mg/kg body weight) was used as therapeutics, a marked reduction in ankle inflammation were also observed (Figure&#x000a0;<xref rid="jcmm14041-fig-0005" ref-type="fig">5</xref>A, left panel). These data show that ankle inflammation could be reduced after HDAC inhibitor therapy to K/BxN serum&#x02010;induced mice.</p><fig fig-type="Figure" xml:lang="en" id="jcmm14041-fig-0005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>
<styled-content style="fixed-case">HDAC</styled-content> inhibitors reduce K/BxN serum&#x02010;induced arthritic inflammation, and bone and cartilage damage in mice. Group of C57<styled-content style="fixed-case">BL</styled-content>/6 mice (8&#x02010;10 mice/group) were induced for development of arthritic inflammation using K/BxN serum (control), and were subjected to i.p. injection of <styled-content style="fixed-case">HDAC</styled-content>i (experimental; either <styled-content style="fixed-case">SAHA</styled-content>, 10&#x000a0;mg/kg body weight; or <styled-content style="fixed-case">SAHA</styled-content> 30&#x000a0;mg/kg body weight; or <styled-content style="fixed-case">MS</styled-content>275, 5&#x000a0;mg/kg body weight) during induction of arthritis for 7&#x000a0;days. (A) Measured ankle inflammations are shown graphically during the development of arthritis for each inhibitor separately, and (*) indicate statistical significance (<italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05) when compared to the respective controls. (B) Haematoxylin and eosin staining of ankles (representative of four animals of each group) showed that reduced bone and cartilage damage after treatment with either of the <styled-content style="fixed-case">HDAC</styled-content> inhibitors (<styled-content style="fixed-case">SAHA</styled-content> or <styled-content style="fixed-case">MS</styled-content>275). Arrowheads indicate the damaged area of the joints. (C)&#x000a0;Clinical score of the histology showed that a damage of bone and cartilage were significantly reduced after treatment with <styled-content style="fixed-case">SAHA</styled-content> or <styled-content style="fixed-case">MS</styled-content>275 inhibitors</p></caption><graphic id="nlm-graphic-9" xlink:href="JCMM-23-1386-g005"/></fig></sec><sec id="jcmm14041-sec-0020"><label>3.6</label><title>Effects of HDAC inhibitors on bone and cartilage damage upon K/BxN serum&#x02010;induced arthritis</title><p>As HDAC inhibitor reduced ankle inflammation in K/BxN serum&#x02010;induced arthritic mice, we next sought to find whether bone and cartilage damage were also reduced. H&#x00026;E staining revealed that a reduced bone and cartilage damage after treatment with either of the HDAC inhibitors like SAHA or MS275 (Figure&#x000a0;<xref rid="jcmm14041-fig-0005" ref-type="fig">5</xref>B). The damage of bone and cartilage were significantly lower in animals (Figure&#x000a0;<xref rid="jcmm14041-fig-0005" ref-type="fig">5</xref>C) that were treated with SAHA (30&#x000a0;mg/kg body weight) or MS275 (5&#x000a0;mg/kg body weight).</p></sec><sec id="jcmm14041-sec-0021"><label>3.7</label><title>To determine interaction between KLF2 and HDAC</title><p>To determine whether KLF2 and HDAC interact with each other in cells, we performed co&#x02010;immunoprecipitation assays by overexpressing KLF2 and HDAC1 through HDAC4 independently transfecting in COS&#x02010;7 cells. Results showed that KLF2 directly binds with HDAC4 in cells (Figure&#x000a0;<xref rid="jcmm14041-fig-0006" ref-type="fig">6</xref>A). To confirm how KLF2 affects on HDAC molecules, KLF2 was overexpressed on RAW 264.7 cells and assessed the expressions of various HDAC molecules. The WB results showed that KLF2 overexpression resulted in higher level of HDAC4 and in decreased level of MMP9 (Figure&#x000a0;<xref rid="jcmm14041-fig-0006" ref-type="fig">6</xref>B). There were very little changes in the levels of HDAC1 and 3. The Western blot data were quantified and shown graphically (Figure&#x000a0;<xref rid="jcmm14041-fig-0006" ref-type="fig">6</xref>C). These results confirm that KLF2 directly interacts with HDAC molecule.</p><fig fig-type="Figure" xml:lang="en" id="jcmm14041-fig-0006" orientation="portrait" position="float"><label>Figure 6</label><caption><p>
<styled-content style="fixed-case">HDAC</styled-content> directly interacts with <styled-content style="fixed-case">KLF</styled-content>2. (A) Co&#x02010;immunoprecipitation assays showed that <styled-content style="fixed-case">KLF</styled-content>2 directly interacts with <styled-content style="fixed-case">HDAC</styled-content>4 molecule. (B) Western blot data revealed that overexpression of <styled-content style="fixed-case">KLF</styled-content>2 resulted in increased level of <styled-content style="fixed-case">HDAC</styled-content>4 and concomitantly decreased level of <styled-content style="fixed-case">MMP</styled-content>9, whereas, levels of <styled-content style="fixed-case">HDAC</styled-content>1 and 3 were minimally changed. (C) Quantified Western blot data of stated molecules are presented graphically</p></caption><graphic id="nlm-graphic-11" xlink:href="JCMM-23-1386-g006"/></fig></sec></sec><sec id="jcmm14041-sec-0022"><label>4</label><title>DISCUSSION</title><p>Rheumatoid arthritis is a progressive autoimmune disease with multifaceted pathobiology involving numerous cells, including monocytes, and various signalling pathways, to drive the inflammation.<xref rid="jcmm14041-bib-0028" ref-type="ref">28</xref> KLF2, a transcriptional factor, is important in regulating endothelial cell development, homeostasis and activation,<xref rid="jcmm14041-bib-0029" ref-type="ref">29</xref> and inhibiting proinflammatory activation of monocytes.<xref rid="jcmm14041-bib-0011" ref-type="ref">11</xref>, <xref rid="jcmm14041-bib-0014" ref-type="ref">14</xref> Therefore, delineating the regulatory role of KLF2 is very important in understanding the diverse roles of KLF2 in RA pathogenesis. On the other hand, HDACi&#x02010;mediated inhibition of inflammatory gene expression<xref rid="jcmm14041-bib-0030" ref-type="ref">30</xref> and immune cell activation<xref rid="jcmm14041-bib-0031" ref-type="ref">31</xref> was reported; however, the exact mechanism is yet to be defined. Therefore, we sought to investigate whether HDACi has any effect on KLF2&#x02010;mediated regulation of RA pathogenesis.</p><p>Among underlying processes in RA, KLF2&#x02010;mediated regulation of osteoclastic differentiation is critically important. Finding the molecules that regulate KLF2 in monocytes could be useful in managing RA pathogenesis. Herein, we found increased KLF2 expressions both in RNA and protein levels after induction with several HDACi molecules (Figure&#x000a0;<xref rid="jcmm14041-fig-0001" ref-type="fig">1</xref>). We next tested HDACi effects on KLF2 expression in&#x000a0;vivo. An increased level of KLF2 expression was found in murine BM, spleen and thymus tissues upon infusion with HDACi (Figure&#x000a0;<xref rid="jcmm14041-fig-0002" ref-type="fig">2</xref>). Interestingly, in&#x000a0;vitro differentiation of monocytes to osteoclasts is remarkably reduced upon HDACi addition (Figure&#x000a0;<xref rid="jcmm14041-fig-0003" ref-type="fig">3</xref>). It is possible that the decreased capability of osteoclast differentiation was because of the up&#x02010;regulated KLF2 level in monocytes. Our finding shows that the up&#x02010;regulated KLF2 is not only decreased the proliferation of monocytes, but also reduced osteoclastic differentiation.</p><p>Out of many inflammatory signals, matrix&#x02010;proteolytic enzyme&#x02010;mediated signalling is highly responsible for destruction of cartilages, bones and articular structures.<xref rid="jcmm14041-bib-0032" ref-type="ref">32</xref> MMPs can cleave adhesion molecules, cytokines, chemokines, growth factors, and their receptors and binding proteins.<xref rid="jcmm14041-bib-0033" ref-type="ref">33</xref> Moreover, they also activate other proteases, and thus, mediate a cascade of severe matrix degradation process.<xref rid="jcmm14041-bib-0033" ref-type="ref">33</xref> Several MMPs are elevated in the synovial fluid and in the serum of RA patients.<xref rid="jcmm14041-bib-0034" ref-type="ref">34</xref> Herein, we show that reductions in osteoclastic differentiation upon HDACi addition to monocytes are associated with decreased expression of MMPs along with increased level of KLF2 (Figure&#x000a0;<xref rid="jcmm14041-fig-0004" ref-type="fig">4</xref>). Therefore, as metalloproteinase proteolytic axis ensures appropriate initiation and stop signals during the inflammatory reaction. Importantly, we found a significant dose&#x02010;dependent reduction in ankle thickness upon HDACi with SAHA or MS275 administration to K/BxN serum&#x02010;induced arthritic mice (Figure&#x000a0;<xref rid="jcmm14041-fig-0005" ref-type="fig">5</xref>). The damage of bone and cartilage was significantly reduced in HDACi&#x02010;treated arthritic mice compared to the untreated control arthritic mice. These data support HDACi's ability to exert anti&#x02010;inflammatory effect on K/BxN serum&#x02010;induced arthritic mice, which is in consistent with the earlier observations with different models.<xref rid="jcmm14041-bib-0035" ref-type="ref">35</xref> Taken together, these data not only show the efficacy of HDACi against RA but also suggests a potential for future therapeutic modality against RA.</p><p>Finally, to determine whether KLF2 and HDAC interact each other in monocytes and mediate an effect on inflammatory transcriptional regulation process. Our data suggests that there is a clear interaction between HDACi and KLF2 in the transcriptional regulation level. We assume that acetylation of histone 3 proteins might play a key role in the HDACi regulated transcription progression, as we found the H3 acetylation is induced by HDACi. Histone acetylation causes alteration in nucleosomal conformation,<xref rid="jcmm14041-bib-0036" ref-type="ref">36</xref> which can increase the accessibility of transcriptional regulatory proteins to chromatin templates.<xref rid="jcmm14041-bib-0037" ref-type="ref">37</xref> Our earlier published data suggests that histone acetylation might result in increased transcriptional activity in monocytes by facilitating p65&#x02010; and c&#x02010;Fos/c&#x02010;Jun&#x02010;dependent transcriptional progression of NF&#x003ba;B and AP1 gene, even in the presence of KLF2.<xref rid="jcmm14041-bib-0011" ref-type="ref">11</xref>, <xref rid="jcmm14041-bib-0014" ref-type="ref">14</xref> However, transcriptional regulation did not lead to inflammatory protein synthesis, rather reduced. Because the level of KLF2 was increased in the presence of HDACi both in&#x000a0;vitro as well as in&#x000a0;vivo<italic>,</italic> that mediated inhibition to the inflammatory gene expression and protein synthesis. In addition, KLF2 directly binds to the HDAC4 in cells (Figure&#x000a0;<xref rid="jcmm14041-fig-0006" ref-type="fig">6</xref>A) and overexpression of KLF2 in monocytes resulted in higher level of HDAC4, and mediated in decreased level of MMP9 molecule (Figure&#x000a0;<xref rid="jcmm14041-fig-0006" ref-type="fig">6</xref>B). These data provide evidence that KLF2 and HDAC interacts each other in monocytes in the transcriptional level and protein level, and resulted in reduction of arthritic inflammation.</p><p>In sum, our data provide evidence that HDACi up&#x02010;regulate KLF2 in monocytes both in&#x000a0;vitro and in&#x000a0;vivo. In addition, HDACi significantly reduce osteoclastic differentiation along with up&#x02010;regulation of the KLF2 and concomitant down&#x02010;regulation of MMPs. Moreover, HDACi reduce K/BxN serum&#x02010;induced arthritic inflammation and joint destruction in mice in a dose&#x02010;dependent manner. Furthermore, KLF2 and HDAC4 interacts each other in monocytes. These findings provide first mechanistic evidence of HDAC&#x02010;HDACi/KLF2&#x02010;axis in reduction of arthritic inflammation.</p></sec><sec id="jcmm14041-sec-0024"><title>DISCLOSURE</title><p>The authors have no conflict of interest. The authors did not receive any fund from commercial sources.</p></sec><sec id="jcmm14041-sec-0025"><title>AUTHOR CONTRIBUTIONS</title><p>All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Dr. Das and The Ohio State University, and Texas Tech University Health Sciences Center have full access to the data of the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study conception, design and manuscript writing: MD and HD. Acquisition of data: MD, DL, MJ, RA, SK and HI. Reagents, analysis and interpretation of data: HD, MD, DL, SK, RA, HI, VP and MKJ.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="jcmm14041-sup-0001"><caption><p>&#x000a0;</p></caption><media xlink:href="JCMM-23-1386-s001.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="jcmm14041-sup-0002"><caption><p>&#x000a0;</p></caption><media xlink:href="JCMM-23-1386-s002.tiff"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="jcmm14041-sec-0023"><title>ACKNOWLEDGEMENTS</title><p>This work was supported in part by National Institutes of Health grants, R01AR068279 (NIAMS), STTR 1R41EY024217 (NEI), STTR 1R41AG057242 (NIA) and The Ohio State University start&#x02010;up fund. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Authors are thankful to Prof. Diane Mathis, PhD, Harvard Medical School, Boston, MA for providing KRN mice and sharing laboratory protocols.</p></ack><ref-list content-type="cited-references" id="jcmm14041-bibl-0001"><title>REFERENCES</title><ref id="jcmm14041-bib-0001"><label>1</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0001">
<string-name>
<surname>Firestein</surname>
<given-names>GS</given-names>
</string-name>, <string-name>
<surname>McInnes</surname>
<given-names>IB</given-names>
</string-name>. <article-title>Immunopathogenesis of rheumatoid arthritis</article-title>. <source xml:lang="en">Immunity</source>. <year>2017</year>;<volume>46</volume>(<issue>2</issue>):<fpage>183</fpage>&#x02010;<lpage>196</lpage>.<pub-id pub-id-type="pmid">28228278</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0002"><label>2</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0002">
<string-name>
<surname>Sokka</surname>
<given-names>T</given-names>
</string-name>. <article-title>Long&#x02010;term outcomes of rheumatoid arthritis</article-title>. <source xml:lang="en">Curr Opin Rheumatol</source>. <year>2009</year>;<volume>21</volume>(<issue>3</issue>):<fpage>284</fpage>&#x02010;<lpage>290</lpage>.<pub-id pub-id-type="pmid">19342954</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0003"><label>3</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0003">
<string-name>
<surname>Puolakka</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Kautiainen</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Mottonen</surname>
<given-names>T</given-names>
</string-name>, et&#x000a0;al. <article-title>Early suppression of disease activity is essential for maintenance of work capacity in patients with recent&#x02010;onset rheumatoid arthritis: five&#x02010;year experience from the FIN&#x02010;RACo trial</article-title>. <source xml:lang="en">Arthritis Rheum</source>. <year>2005</year>;<volume>52</volume>(<issue>1</issue>):<fpage>36</fpage>&#x02010;<lpage>41</lpage>.<pub-id pub-id-type="pmid">15641055</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0004">
<string-name>
<surname>Fox</surname>
<given-names>DA</given-names>
</string-name>. <article-title>The role of T cells in the immunopathogenesis of rheumatoid arthritis: new perspectives</article-title>. <source xml:lang="en">Arthritis Rheum</source>. <year>1997</year>;<volume>40</volume>(<issue>4</issue>):<fpage>598</fpage>&#x02010;<lpage>609</lpage>.<pub-id pub-id-type="pmid">9125240</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0005"><label>5</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0005">
<string-name>
<surname>Bennink</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Thurlings</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>van Hemert</surname>
<given-names>FJ</given-names>
</string-name>, et&#x000a0;al. <article-title>Biodistribution and radiation dosimetry of 99mTc&#x02010;HMPAO&#x02010;labeled monocytes in patients with rheumatoid arthritis</article-title>. <source xml:lang="en">J Nucl Med</source>. <year>2008</year>;<volume>49</volume>(<issue>8</issue>):<fpage>1380</fpage>&#x02010;<lpage>1385</lpage>.<pub-id pub-id-type="pmid">18632808</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0006">
<string-name>
<surname>Agarwal</surname>
<given-names>SK</given-names>
</string-name>, <string-name>
<surname>Brenner</surname>
<given-names>MB</given-names>
</string-name>. <article-title>Role of adhesion molecules in synovial inflammation</article-title>. <source xml:lang="en">Curr Opin Rheumatol</source>. <year>2006</year>;<volume>18</volume>(<issue>3</issue>):<fpage>268</fpage>&#x02010;<lpage>276</lpage>.<pub-id pub-id-type="pmid">16582691</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0007"><label>7</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0007">
<string-name>
<surname>Komano</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Nanki</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hayashida</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Taniguchi</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Miyasaka</surname>
<given-names>N</given-names>
</string-name>. <article-title>Identification of a human peripheral blood monocyte subset that differentiates into osteoclasts</article-title>. <source xml:lang="en">Arthritis Res Ther</source>. <year>2006</year>;<volume>8</volume>(<issue>5</issue>):<fpage>R152</fpage>.<pub-id pub-id-type="pmid">16987426</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0008"><label>8</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0008">
<string-name>
<surname>Kinne</surname>
<given-names>RW</given-names>
</string-name>, <string-name>
<surname>Stuhlmuller</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Burmester</surname>
<given-names>GR</given-names>
</string-name>. <article-title>Cells of the synovium in rheumatoid arthritis. Macrophages</article-title>. <source xml:lang="en">Arthritis Res Ther</source>. <year>2007</year>;<volume>9</volume>(<issue>6</issue>):<fpage>224</fpage>.<pub-id pub-id-type="pmid">18177511</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0009">
<string-name>
<surname>Buckley</surname>
<given-names>AF</given-names>
</string-name>, <string-name>
<surname>Kuo</surname>
<given-names>CT</given-names>
</string-name>, <string-name>
<surname>Leiden</surname>
<given-names>JM</given-names>
</string-name>. <article-title>Transcription factor LKLF is sufficient to program T cell quiescence via a c&#x02010;Myc&#x02013;dependent pathway</article-title>. <source xml:lang="en">Nat Immunol</source>. <year>2001</year>;<volume>2</volume>(<issue>8</issue>):<fpage>698</fpage>&#x02010;<lpage>704</lpage>.<pub-id pub-id-type="pmid">11477405</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0010">
<string-name>
<surname>Hart</surname>
<given-names>GT</given-names>
</string-name>, <string-name>
<surname>Peery</surname>
<given-names>SL</given-names>
</string-name>, <string-name>
<surname>Hamilton</surname>
<given-names>SE</given-names>
</string-name>, <string-name>
<surname>Jameson</surname>
<given-names>SC</given-names>
</string-name>. <article-title>Cutting edge: Kruppel&#x02010;like factor 2 is required for phenotypic maintenance but not development of B1 B cells</article-title>. <source xml:lang="en">J Immunol</source>. <year>2012</year>;<volume>189</volume>(<issue>7</issue>):<fpage>3293</fpage>&#x02010;<lpage>3297</lpage>.<pub-id pub-id-type="pmid">22942434</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0011">
<string-name>
<surname>Das</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Kumar</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>Z</given-names>
</string-name>, et&#x000a0;al. <article-title>Kruppel&#x02010;like factor 2 (KLF2) regulates proinflammatory activation of monocytes</article-title>. <source xml:lang="en">Proc Natl Acad Sci U S A</source>. <year>2006</year>;<volume>103</volume>(<issue>17</issue>):<fpage>6653</fpage>&#x02010;<lpage>6658</lpage>.<pub-id pub-id-type="pmid">16617118</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0012">
<string-name>
<surname>Mahabeleshwar</surname>
<given-names>GH</given-names>
</string-name>, <string-name>
<surname>Kawanami</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Sharma</surname>
<given-names>N</given-names>
</string-name>, et&#x000a0;al. <article-title>The myeloid transcription factor KLF2 regulates the host response to polymicrobial infection and endotoxic shock</article-title>. <source xml:lang="en">Immunity</source>. <year>2011</year>;<volume>34</volume>(<issue>5</issue>):<fpage>715</fpage>&#x02010;<lpage>728</lpage>.<pub-id pub-id-type="pmid">21565532</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0013">
<string-name>
<surname>Kuo</surname>
<given-names>CT</given-names>
</string-name>, <string-name>
<surname>Veselits</surname>
<given-names>ML</given-names>
</string-name>, <string-name>
<surname>Barton</surname>
<given-names>KP</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Clendenin</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Leiden</surname>
<given-names>JM</given-names>
</string-name>. <article-title>The LKLF transcription factor is required for normal tunica media formation and blood vessel stabilization during murine embryogenesis</article-title>. <source xml:lang="en">Genes Dev</source>. <year>1997</year>;<volume>11</volume>(<issue>22</issue>):<fpage>2996</fpage>&#x02010;<lpage>3006</lpage>.<pub-id pub-id-type="pmid">9367982</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0014">
<string-name>
<surname>Das</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Joseph</surname>
<given-names>M</given-names>
</string-name>, et&#x000a0;al. <article-title>Kruppel&#x02010;like factor 2 (KLF2) regulates monocyte differentiation and functions in mBSA and IL&#x02010;1&#x003b2;&#x02010;induced arthritis</article-title>. <source xml:lang="en">Curr Mol Med</source>. <year>2012</year>;<volume>12</volume>(<issue>2</issue>):<fpage>113</fpage>&#x02010;<lpage>125</lpage>.<pub-id pub-id-type="pmid">22280353</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0015">
<string-name>
<surname>West</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Johnstone</surname>
<given-names>RW</given-names>
</string-name>. <article-title>New and emerging HDAC inhibitors for cancer treatment</article-title>. <source xml:lang="en">J Clin Invest</source>. <year>2014</year>;<volume>124</volume>(<issue>1</issue>):<fpage>30</fpage>&#x02010;<lpage>39</lpage>.<pub-id pub-id-type="pmid">24382387</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0016">
<string-name>
<surname>Bannister</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Kouzarides</surname>
<given-names>T</given-names>
</string-name>. <article-title>Regulation of chromatin by histone modifications</article-title>. <source xml:lang="en">Cell Res</source>. <year>2011</year>;<volume>21</volume>(<issue>3</issue>):<fpage>381</fpage>&#x02010;<lpage>395</lpage>.<pub-id pub-id-type="pmid">21321607</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0017"><label>17</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0017">
<string-name>
<surname>Singh</surname>
<given-names>BN</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Hwa</surname>
<given-names>YL</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Dowdy</surname>
<given-names>SC</given-names>
</string-name>, <string-name>
<surname>Jiang</surname>
<given-names>SW</given-names>
</string-name>. <article-title>Nonhistone protein acetylation as cancer therapy targets</article-title>. <source xml:lang="en">Expert Rev Anticancer Ther</source>. <year>2010</year>;<volume>10</volume>(<issue>6</issue>):<fpage>935</fpage>&#x02010;<lpage>954</lpage>.<pub-id pub-id-type="pmid">20553216</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0018">
<string-name>
<surname>Leus</surname>
<given-names>NG</given-names>
</string-name>, <string-name>
<surname>Zwinderman</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Dekker</surname>
<given-names>FJ</given-names>
</string-name>. <article-title>Histone deacetylase 3 (HDAC 3) as emerging drug target in NF&#x02010;kappaB&#x02010;mediated inflammation</article-title>. <source xml:lang="en">Curr Opin Chem Biol</source>. <year>2016</year>;<volume>33</volume>:<fpage>160</fpage>&#x02010;<lpage>168</lpage>.<pub-id pub-id-type="pmid">27371876</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0019"><label>19</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0019">
<string-name>
<surname>Das</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Groh</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Kuijl</surname>
<given-names>C</given-names>
</string-name>, et&#x000a0;al. <article-title>MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen&#x02010;dependent effector function</article-title>. <source xml:lang="en">Immunity</source>. <year>2001</year>;<volume>15</volume>(<issue>1</issue>):<fpage>83</fpage>&#x02010;<lpage>93</lpage>.<pub-id pub-id-type="pmid">11485740</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0020">
<string-name>
<surname>Das</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Abdulhameed</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Joseph</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Sakthivel</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Mao</surname>
<given-names>HQ</given-names>
</string-name>, <string-name>
<surname>Pompili</surname>
<given-names>VJ</given-names>
</string-name>. <article-title>Ex vivo nanofiber expansion and genetic modification of human cord blood&#x02010;derived progenitor/stem cells enhances vasculogenesis</article-title>. <source xml:lang="en">Cell Transplant</source>. <year>2009</year>;<volume>18</volume>(<issue>3</issue>):<fpage>305</fpage>&#x02010;<lpage>318</lpage>.<pub-id pub-id-type="pmid">19558779</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0021">
<string-name>
<surname>McMichael</surname>
<given-names>BK</given-names>
</string-name>, <string-name>
<surname>Cheney</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>BS</given-names>
</string-name>. <article-title>Myosin X regulates sealing zone patterning in osteoclasts through linkage of podosomes and microtubules</article-title>. <source xml:lang="en">J Biol Chem</source>. <year>2010</year>;<volume>285</volume>(<issue>13</issue>):<fpage>9506</fpage>&#x02010;<lpage>9515</lpage>.<pub-id pub-id-type="pmid">20081229</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0022"><label>22</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0022">
<string-name>
<surname>Kouskoff</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Korganow</surname>
<given-names>AS</given-names>
</string-name>, <string-name>
<surname>Duchatelle</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Degott</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Benoist</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Mathis</surname>
<given-names>D</given-names>
</string-name>. <article-title>Organ&#x02010;specific disease provoked by systemic autoimmunity</article-title>. <source xml:lang="en">Cell</source>. <year>1996</year>;<volume>87</volume>(<issue>5</issue>):<fpage>811</fpage>&#x02010;<lpage>822</lpage>.<pub-id pub-id-type="pmid">8945509</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0023">
<string-name>
<surname>Jacobs</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Pettit</surname>
<given-names>AR</given-names>
</string-name>, <string-name>
<surname>Shinohara</surname>
<given-names>ML</given-names>
</string-name>, et&#x000a0;al. <article-title>Lack of requirement of osteopontin for inflammation, bone erosion, and cartilage damage in the K/BxN model of autoantibody&#x02010;mediated arthritis</article-title>. <source xml:lang="en">Arthritis Rheum</source>. <year>2004</year>;<volume>50</volume>(<issue>8</issue>):<fpage>2685</fpage>&#x02010;<lpage>2694</lpage>.<pub-id pub-id-type="pmid">15334485</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0024"><label>24</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0024">
<string-name>
<surname>Staite</surname>
<given-names>ND</given-names>
</string-name>, <string-name>
<surname>Richard</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Aspar</surname>
<given-names>DG</given-names>
</string-name>, <string-name>
<surname>Franz</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Galinet</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Dunn</surname>
<given-names>CJ</given-names>
</string-name>. <article-title>Induction of an acute erosive monarticular arthritis in mice by interleukin&#x02010;1 and methylated bovine serum albumin</article-title>. <source xml:lang="en">Arthritis Rheum</source>. <year>1990</year>;<volume>33</volume>(<issue>2</issue>):<fpage>253</fpage>&#x02010;<lpage>260</lpage>.<pub-id pub-id-type="pmid">2306293</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0025">
<string-name>
<surname>Bischof</surname>
<given-names>RJ</given-names>
</string-name>, <string-name>
<surname>Zafiropoulos</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Hamilton</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Campbell</surname>
<given-names>IK</given-names>
</string-name>. <article-title>Exacerbation of acute inflammatory arthritis by the colony&#x02010;stimulating factors CSF&#x02010;1 and granulocyte macrophage (GM)&#x02010;CSF: evidence of macrophage infiltration and local proliferation</article-title>. <source xml:lang="en">Clin Exp Immunol</source>. <year>2000</year>;<volume>119</volume>(<issue>2</issue>):<fpage>361</fpage>&#x02010;<lpage>367</lpage>.<pub-id pub-id-type="pmid">10632676</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0026">
<string-name>
<surname>Schett</surname>
<given-names>G</given-names>
</string-name>. <article-title>Cells of the synovium in rheumatoid arthritis. Osteoclasts</article-title>. <source xml:lang="en">Arthritis Res Ther</source>. <year>2007</year>;<volume>9</volume>(<issue>1</issue>):<fpage>203</fpage>.<pub-id pub-id-type="pmid">17316459</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0027">
<string-name>
<surname>Soderstrom</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Stein</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Colmenero</surname>
<given-names>P</given-names>
</string-name>, et&#x000a0;al. <article-title>Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis</article-title>. <source xml:lang="en">Proc Natl Acad Sci U S A</source>. <year>2010</year>;<volume>107</volume>(<issue>29</issue>):<fpage>13028</fpage>&#x02010;<lpage>13033</lpage>.<pub-id pub-id-type="pmid">20615964</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0028">
<string-name>
<surname>Udalova</surname>
<given-names>IA</given-names>
</string-name>, <string-name>
<surname>Mantovani</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Feldmann</surname>
<given-names>M</given-names>
</string-name>. <article-title>Macrophage heterogeneity in the context of rheumatoid arthritis</article-title>. <source xml:lang="en">Nat Rev Rheumatol</source>. <year>2016</year>;<volume>12</volume>(<issue>8</issue>):<fpage>472</fpage>&#x02010;<lpage>485</lpage>.<pub-id pub-id-type="pmid">27383913</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0029">
<string-name>
<surname>Atkins</surname>
<given-names>GB</given-names>
</string-name>, <string-name>
<surname>Jain</surname>
<given-names>MK</given-names>
</string-name>. <article-title>Role of Kruppel&#x02010;like transcription factors in endothelial biology</article-title>. <source xml:lang="en">Circ Res</source>. <year>2007</year>;<volume>100</volume>(<issue>12</issue>):<fpage>1686</fpage>&#x02010;<lpage>1695</lpage>.<pub-id pub-id-type="pmid">17585076</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0030">
<string-name>
<surname>Angiolilli</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Kabala</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Grabiec</surname>
<given-names>AM</given-names>
</string-name>, et&#x000a0;al. <article-title>Histone deacetylase 3 regulates the inflammatory gene expression programme of rheumatoid arthritis fibroblast&#x02010;like synoviocytes</article-title>. <source xml:lang="en">Ann Rheum Dis</source>. <year>2016</year>;<volume>76</volume>(<issue>1</issue>):<fpage>277</fpage>&#x02010;<lpage>285</lpage>.<pub-id pub-id-type="pmid">27457515</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0031">
<string-name>
<surname>Vojinovic</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Damjanov</surname>
<given-names>N</given-names>
</string-name>. <article-title>HDAC inhibition in rheumatoid arthritis and juvenile idiopathic arthritis</article-title>. <source xml:lang="en">Mol Med</source>. <year>2011</year>;<volume>17</volume>(<issue>5&#x02013;6</issue>):<fpage>397</fpage>&#x02010;<lpage>403</lpage>.<pub-id pub-id-type="pmid">21308151</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0032">
<string-name>
<surname>Yasuda</surname>
<given-names>T</given-names>
</string-name>. <article-title>Cartilage destruction by matrix degradation products</article-title>. <source xml:lang="en">Mod Rheumatol</source>. <year>2006</year>;<volume>16</volume>(<issue>4</issue>):<fpage>197</fpage>&#x02010;<lpage>205</lpage>.<pub-id pub-id-type="pmid">16906368</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0033">
<string-name>
<surname>Sternlicht</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Werb</surname>
<given-names>Z</given-names>
</string-name>. <article-title>How matrix metalloproteinases regulate cell behavior</article-title>. <source xml:lang="en">Annu Rev Cell Dev Biol</source>. <year>2001</year>;<volume>17</volume>:<fpage>463</fpage>&#x02010;<lpage>516</lpage>.<pub-id pub-id-type="pmid">11687497</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0034">
<string-name>
<surname>Tchetverikov</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Ronday</surname>
<given-names>HK</given-names>
</string-name>, <string-name>
<surname>Van El</surname>
<given-names>B</given-names>
</string-name>, et&#x000a0;al. <article-title>MMP profile in paired serum and synovial fluid samples of patients with rheumatoid arthritis</article-title>. <source xml:lang="en">Ann Rheum Dis</source>. <year>2004</year>;<volume>63</volume>(<issue>7</issue>):<fpage>881</fpage>&#x02010;<lpage>883</lpage>.<pub-id pub-id-type="pmid">15194590</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0035">
<string-name>
<surname>Adcock</surname>
<given-names>IM</given-names>
</string-name>. <article-title>HDAC inhibitors as anti&#x02010;inflammatory agents</article-title>. <source xml:lang="en">Br J Pharmacol</source>. <year>2007</year>;<volume>150</volume>(<issue>7</issue>):<fpage>829</fpage>&#x02010;<lpage>831</lpage>.<pub-id pub-id-type="pmid">17325655</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0036">
<string-name>
<surname>Workman</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Kingston</surname>
<given-names>RE</given-names>
</string-name>. <article-title>Alteration of nucleosome structure as a mechanism of transcriptional regulation</article-title>. <source xml:lang="en">Annu Rev Biochem</source>. <year>1998</year>;<volume>67</volume>:<fpage>545</fpage>&#x02010;<lpage>579</lpage>.<pub-id pub-id-type="pmid">9759497</pub-id></mixed-citation></ref><ref id="jcmm14041-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="jcmm14041-cit-0037">
<string-name>
<surname>Eberharter</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Becker</surname>
<given-names>PB</given-names>
</string-name>. <article-title>Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics</article-title>. <source xml:lang="en">EMBO Rep</source>. <year>2002</year>;<volume>3</volume>(<issue>3</issue>):<fpage>224</fpage>&#x02010;<lpage>229</lpage>.<pub-id pub-id-type="pmid">11882541</pub-id></mixed-citation></ref></ref-list></back></article>